Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetratricopeptide repeat domain 3 pseudogene 1 (TTC3P1, also referred to as RNF105L) is annotated as a pseudogene in the human genome. Pseudogenes are genetic elements that resemble protein-coding genes but contain mutations that prevent them from being translated into functional proteins. There are no reports in the scientific literature of TTC3P1 acting as an enzyme, receptor, transporter, or other acknowledged drug target. Likewise, RNF105L appears in gene databases only as an alternative name or predicted locus designation for this pseudogene, not as a characterized gene or protein. There are no known biological functions, disease associations, or interacting drugs for this locus. Therefore, TTC3P1 cannot be classified as a therapeutic target and is generally considered a nonfunctional genetic element.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetratricopeptide repeat domain 3 pseudogene 1 (TTC3P1).